GlaxoSmithKline_NNP 176_CD Share_NN capital_NN Nature_NN of_IN trading_NN market_NN Glaxo_NNP Wellcome_NNP The_NNP Ordinary_NNP Shares_NNP of_IN the_DT company_NN were_VBD listed_VBN on_IN the_DT London_NNP Fiscal_JJ period_NN from_IN 1st_CD January_NNP to_TO 26th_JJ December_NNP 2000_CD Stock_NNP Exchange_NNP on_IN 27th_JJ December_NNP 2000_CD ._.
The_DT shares_NNS were_VBD also_RB Pence_NNP per_IN share_NN listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP in_IN the_DT form_NN of_IN American_NNP High_NNP Low_NNP Depositary_NNP Shares_NNP ADSs_NNPS from_IN the_DT same_JJ date_NN ._.
2000 2110 1440_CD The_DT following_JJ table_NN sets_VBZ out_RP ,_, for_IN the_DT periods_NNS indicated_VBD ,_, the_DT high_JJ and_CC low_JJ middle_JJ market_NN closing_VBG quotations_NNS in_IN pence_NN for_IN the_DT shares_NNS Fiscal_JJ period_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP ,_, as_IN derived_VBN from_IN its_PRP$ Daily_NNP Official_NNP from_IN 1st_CD January_NNP to_TO 26th_JJ December_NNP 2000_CD US_NNP dollars_NNS per_IN ADS_NNPS List_NN ,_, and_CC the_DT high_JJ and_CC low_JJ last_JJ reported_VBD sales_NNS prices_NNS in_IN US_NNP dollars_NNS for_IN the_DT ADSs_NNS on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ,_, as_IN derived_VBN from_IN High_NNP Low_NNP the_DT New_NNP York_NNP Stock_NNP Exchange_NNP Composite_NNP Tape_NNP ._.
3_CD 2000_CD 63_CD 4_CD 46_CD Information_NN relating_VBG to_TO the_DT share_NN and_CC ADS_NNPS prices_NNS for_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP prior_RB to_TO the_DT date_NN of_IN SmithKline_NNP Beecham_NNP the_DT merger_NN is_VBZ also_RB given_VBN ._.
At_IN 25th_JJ February_NNP 2005_CD ,_, the_DT number_NN of_IN holders_NNS of_IN record_NN of_IN shares_NNS in_IN the_DT USA_NNP was_VBD 1,187_CD with_IN holdings_NNS of_IN 1,776,334_CD shares_NNS ,_, and_CC the_DT number_NN of_IN registered_VBN holders_NNS of_IN the_DT ADRs_NNPS was_VBD 44,537_CD with_IN holdings_NNS of_IN 401,140,809_CD ADRs_NNS ._.
Certain_NNP of_IN these_DT shares_NNS and_CC ADRs_NNS were_VBD held_VBN by_IN brokers_NNS or_CC other_JJ nominees_NNS ,_, as_IN a_DT result_NN the_DT number_NN of_IN holders_NNS of_IN record_NN or_CC registered_VBN holders_NNS in_IN the_DT USA_NNP is_VBZ not_RB representative_JJ of_IN the_DT number_NN of_IN beneficial_JJ holders_NNS or_CC of_IN the_DT residence_NN of_IN beneficial_JJ holders_NNS ._.
Control_NN of_IN company_NN As_IN far_RB as_RB is_VBZ known_VBN to_TO the_DT company_NN ,_, it_PRP is_VBZ not_RB directly_RB or_CC indirectly_RB owned_VBN or_CC controlled_VBN by_IN one_CD or_CC more_JJR corporations_NNS or_CC by_IN any_DT government_NN ._.
The_DT company_NN does_VBZ not_RB know_VB of_IN any_DT arrangements_NNS ,_, the_DT operation_NN of_IN which_WDT might_MD result_VB in_IN a_DT change_NN in_IN control_NN of_IN the_DT company_NN ._.
Substantial_JJ shareholdings_NNS At_IN 25th_JJ February_NNP 2005_CD ,_, the_DT company_NN had_VBD received_VBN notification_NN of_IN the_DT following_VBG interests_NNS of_IN three_CD per_IN cent_NN or_CC more_JJR in_IN the_DT shares_NNS in_IN issue_NN ,_, excluding_VBG Treasury_NNP shares_NNS :_: BNY_NNP Nominees_NNPS Limited_NNP holds_VBZ 802,281,619_CD shares_NNS representing_VBG 13.68_CD per_IN cent_NN ._.
These_DT shares_NNS are_VBP held_VBN on_IN behalf_NN of_IN holders_NNS of_IN ADRs_NNS ,_, which_WDT evidence_NN ADSs_NNS ._.
Legal_NNP &_CC General_NNP Investment_NNP Management_NNP Limited_NNP holds_VBZ 215,495,981_CD shares_NNS representing_VBG 3.67_CD per_IN cent_NN ._.
Barclays_NNP plc_NN holds_VBZ 229,512,017_CD shares_NNS representing_VBG 3.91_CD per_IN cent_NN ._.
As_IN far_RB as_RB is_VBZ known_VBN to_TO the_DT company_NN ,_, no_DT other_JJ person_NN was_VBD the_DT owner_NN of_IN three_CD per_IN cent_NN or_CC more_JJR of_IN the_DT shares_NNS in_IN issue_NN ,_, excluding_VBG Treasury_NNP shares_NNS of_IN the_DT company_NN ._.
Directors_NNS and_CC Officers_NNS The_DT interests_NNS of_IN the_DT Directors_NNS and_CC Officers_NNS of_IN the_DT company_NN ,_, as_IN defined_VBN in_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, in_IN share_NN options_NNS of_IN the_DT company_NN are_VBP given_VBN in_IN the_DT Remuneration_NNP Report_NNP pages_NNS 43_CD to_TO 58_CD ._.
Exchange_NNP controls_NNS and_CC other_JJ limitations_NNS affecting_VBG security_NN holders_NNS There_EX are_VBP currently_RB no_DT UK_NNP laws_NNS ,_, decrees_NNS or_CC regulations_NNS restricting_VBG the_DT import_NN or_CC export_NN of_IN capital_NN or_CC affecting_VBG the_DT remittance_NN of_IN dividends_NNS or_CC other_JJ payments_NNS to_TO holders_NNS of_IN the_DT companys_NNS shares_NNS who_WP are_VBP non-residents_NNS of_IN the_DT UK_NNP ._.
There_EX are_VBP no_DT limitations_NNS relating_VBG only_RB to_TO non-residents_NNS of_IN the_DT UK_NNP under_IN English_NNP law_NN or_CC the_DT companys_NNS Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP on_IN the_DT right_NN to_TO be_VB a_DT holder_NN of_IN ,_, and_CC to_TO vote_VB in_IN respect_NN of_IN ,_, the_DT companys_NNS shares_NNS ._.
Documents_NNS on_IN display_NN The_DT Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN the_DT company_NN and_CC other_JJ documents_NNS referred_VBD to_TO in_IN this_DT Annual_JJ Report_NNP are_VBP available_JJ for_IN inspection_NN at_IN the_DT Registered_NNP Office_NNP of_IN the_DT company_NN ._.
Publications_NNP This_DT year_NN GlaxoSmithKline_NNP is_VBZ again_RB producing_VBG a_DT Corporate_JJ Responsibility_NN Report_NNP covering_VBG performance_NN in_IN areas_NNS including_VBG community_NN investment_NN ,_, business_NN ethics_NNS and_CC integrity_NN ,_, access_NN to_TO medicines_NNS ,_, R&D_NNP and_CC environmental_JJ health_NN and_CC safety_NN ._.
The_DT report_NN will_MD be_VB published_VBN on_IN the_DT website_NN at_IN the_DT end_NN of_IN March_NNP ._.
